In studies examining the relationship between ERCC1 polymorphisms and the responsiveness of patients with non-small cell lung cancer treated with cisplatin, the results showed that ERCC1 polymorphisms were not associated with platinum responsiveness and there was no evidence of a potential prognostic role in a Caucasian population [6, 7]. This evidence concerns the gene ERCC1 and non-small cell lung carcinoma.